PriceTargets.com logo

Nxera Pharma - SOLTF Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.30 As of 04/26/2024 03:42 PM ET
▼ -0.42 (-4.32%)

This chart shows the closing price for SOLTF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nxera Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SOLTF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SOLTF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Nxera Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.30.

This chart shows the closing price for SOLTF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 2 polled investment analysts is to sell stock in Nxera Pharma. This Sell consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/28/2023CitigroupDowngradeBuy ➝ Sell
6/27/2023Jefferies Financial GroupDowngradeBuy ➝ Underperform
3/12/2021Jefferies Financial GroupInitiated CoverageBuy
1/6/2021Smith Barney CitigroupUpgradeNeutral ➝ Outperform
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Nxera Pharma logo
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $9.30
Low: $9.30
High: $9.30

50 Day Range

MA: $10.10
Low: $8.72
High: $13.43

52 Week Range

Now: $9.30
Low: $8.56
High: $22.78

Volume

1,000 shs

Average Volume

2,814 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Nxera Pharma?

The following sell-side analysts have issued research reports on Nxera Pharma in the last year: Citigroup Inc., and Jefferies Financial Group Inc..
View the latest analyst ratings for SOLTF.

What is the current price target for Nxera Pharma?

0 Wall Street analysts have set twelve-month price targets for Nxera Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Nxera Pharma in the next year.
View the latest price targets for SOLTF.

What is the current consensus analyst rating for Nxera Pharma?

Nxera Pharma currently has 2 sell ratings from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe SOLTF will underperform the market and that investors should sell shares of Nxera Pharma.
View the latest ratings for SOLTF.

What other companies compete with Nxera Pharma?

Other companies that are similar to Nxera Pharma include 180 Life Sciences, 3SBio, 60 Degrees Pharmaceuticals, Abcam and Adocia. Learn More about companies similar to Nxera Pharma.

How do I contact Nxera Pharma's investor relations team?

Nxera Pharma's physical mailing address is PMO Hanzomon, 11/F, Tokyo, 102-0083. The company's listed phone number is (135) 210-3290. The official website for Nxera Pharma is www.sosei.com. Learn More about contacing Nxera Pharma investor relations.